ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource‐limited settings
Journal of Pediatric Gastroenterology and Nutrition · 2024
DOI: 10.1002/jpn3.12160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2024. Verfasst von Giuseppe Indolfi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department NEUROFARBA University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Hepatitis C, Benzimidazoles, Benzopyrans. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide, with more than three million viraemic adolescents and children. Treatment of adults with HCV infection and HCV‐related liver disease has advanced considerably thanks to development and improvements in therapy. Direct‐acting antiviral regimens are safe and effective. Three regimens with pangenotypic activity (glecaprevir/pibrentasvir, sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir) and three regimens with genotype‐specific activity (sofosbuvir/ribavirin, sofosbuvir/ledipasvir and elbasvir/grazoprevir) have been approved with age‐specific limitation for treatment of children with chronic hepatitis C by the European Medicines Agency and the United States Food and Drug Administration. The World Health Organization has set the ambitious target to eliminate hepatitis C as a major public health threat by 2030 and based its actions against HCV on the large use of direct acting antivirals. These updated European Society for Pediatric Gastroenterology, Hepatology and Nutrition recommendations on treatment of hepatitis C describe the optimal therapeutic management of adolescents and children with HCV infection including specific indications for those living in resource‐limited settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department NEUROFARBA University of Florence, Florence, Italy.
- Paediatric and Liver Unit, Meyer Children's Hospital IRCCS, Firenze, Italy.
- Pediatric Gastroenterology, Hepatology and Liver Transplant, AdventHealth for Children, AdventHealth Transplant Institute, Orlando, Florida, USA.
- Boston Children's Hospital, Boston, Massachusetts, USA.
- Department of Paediatrics, Children's Hospital, Ain Shams University, Cairo, Egypt.
- Department of Paediatrics, Karolinska University Hospital, CLINTEC, Karolinska Institutet, Stockholm, Sweden.
Zitieren
APA
Indolfi, G., Gonzalez-Peralta, R. P., Jonas, M. M., Sayed, M. H., Fischler, B., Sokal, E., Wirth, S., Nicastro, E., & Hepatology Committee of the ESPGHAN (2024). ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource‐limited settings. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.12160
Vancouver
Indolfi G, Gonzalez-Peralta RP, Jonas MM, Sayed MH, Fischler B, Sokal E, et al. ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource‐limited settings. Journal of Pediatric Gastroenterology and Nutrition. 2024. doi:10.1002/jpn3.12160
BibTeX
@article{Indolfi2024,
author = {Indolfi, Giuseppe and Gonzalez-Peralta, Regino P and Jonas, Maureen M and Sayed, Manal Hamdy-El and Fischler, Björn and Sokal, Etienne and Wirth, Stefan and Nicastro, Emanuele and Hepatology Committee of the ESPGHAN, Hepatology Committee of the ESPGHAN},
title = {ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource‐limited settings},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2024},
doi = {10.1002/jpn3.12160}
}
EUVIMED